FDA Drug-Device Submission Models Explained: Complete Guide for Regulatory Affairs and Compliance FDA Drug-Device Submission Models: Strategic Regulatory Guide for Pharma and MedTech Introduction to FDA Drug-Device Submission Models Drug-device combination products are becoming increasingly common in therapeutic innovation, from prefilled syringes and autoinjectors to implantable drug delivery systems and digital health devices. The US Food and Drug Administration (FDA) regulates these products through multiple submission models, depending on the primary mode of action (PMOA). The FDA’s Office of Combination Products (OCP) plays a pivotal role in assigning review responsibility to CDER, CBER, or CDRH. By 2025, the complexity of…

FDA Regulatory Centers for Combination Products: CDER, CBER, CDRH FDA Regulatory Centers for Combination Products: CDER, CBER, CDRH In the ever-evolving landscape of pharmaceuticals, understanding the regulatory pathways for combination products is critical for healthcare professionals involved in drug development. Combination products are therapeutic or diagnostic products that combine drugs, devices, and/or biological products. This comprehensive guide aims to provide a detailed, step-by-step approach to navigating the regulatory frameworks established by the FDA’s centers: the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Devices and Radiological Health (CDRH). Step…

RFD (Request for Designation): When and How to File RFD (Request for Designation): When and How to File In the landscape of regulatory affairs, understanding the intricacies of submitting a Request for Designation (RFD) to the FDA is crucial for firms working with combination products. This comprehensive guide delineates practical steps, regulatory requirements, and documentation expectations, paving the way for compliance and successful product development. This tutorial will benefit regulatory professionals involved in FDA combination product consulting, providing a structured approach to RFD submissions and the regulatory process surrounding them. Step 1: Understand the Definition and Types of Combination Products…

505(b)(2), NDA, BLA, and PMA: Mapping Drug-Device Regulatory Pathways 505(b)(2), NDA, BLA, and PMA: Mapping Drug-Device Regulatory Pathways This comprehensive guide aims to provide a step-by-step tutorial on the various regulatory pathways available under the FDA for drug-device products, focusing on the 505(b)(2) applications, New Drug Applications (NDA), Biologics License Applications (BLA), and Premarket Approval (PMA). Understanding these pathways, along with clear documentation requirements and practical actions, can significantly facilitate FDA combination product consulting endeavors. Step 1: Understanding the Framework of Combination Products Combination products are therapeutic products that combine drugs, devices, and/or biological products. The FDA classifies these based…

Single vs Dual Application Strategies at FDA for Combination Products Single vs Dual Application Strategies at FDA for Combination Products In the complex landscape of regulatory submissions, combination products—those consisting of a drug, device, or biological product—pose significant challenges and opportunities. Emerging regulatory frameworks necessitate a comprehensive understanding of the optimal application strategy to ensure compliance and expedite market entry. This step-by-step tutorial guide will navigate the intricacies of the FDA’s submission models for combination products, focusing on single versus dual application strategies. By adhering to the guidelines from the FDA, professionals in regulatory affairs, quality assurance, and commercial operations…

FDA’s Office of Combination Products (OCP): Structure and Functions FDA’s Office of Combination Products (OCP): Structure and Functions The regulatory landscape for combination products can often be intricate and demanding. This article provides a detailed, step-by-step tutorial for professionals involved with FDA combination product consulting, focusing on the role of the FDA’s Office of Combination Products (OCP). This guide serves as a thorough resource for understanding and navigating the structure and functions of the OCP, particularly relevant for regulatory affairs professionals, regulatory operations, quality assurance teams, and commercial teams in the US pharmaceutical landscape. Step 1: Understanding Combination Products Combination…

How to Address Human Factors in FDA Combination Product Reviews How to Address Human Factors in FDA Combination Product Reviews Addressing human factors in FDA combination product reviews is a critical component for ensuring product safety and efficacy. This step-by-step guide is tailored for US regulatory professionals involved in the submission processes for combination products. By following these steps, you will gain insights into effectively integrating human factors into your regulatory submissions. This comprehensive approach will enhance your FDA combination product consulting efforts. Step 1: Understanding Human Factors in Combination Products Human factors engineering (HFE) encompasses the study and evaluation…

Cross-Center Consultations: Coordination Between FDA Centers Cross-Center Consultations: Coordination Between FDA Centers The regulation of combination products within the United States requires an intricate understanding of the operational frameworks of various FDA centers. For stakeholders, including Regulatory Affairs, Commercial teams, and Quality Assurance, navigating this landscape necessitates a focused approach to cross-center consultations. This tutorial provides a step-by-step guide to effectively coordinating with relevant FDA Centers—specifically, the Office of Combination Products (OCP), the Center for Drug Evaluation and Research (CDER), and the Center for Devices and Radiological Health (CDRH)—to ensure an efficient regulatory pathway for combination products. Step 1: Understand…

Use of Pre-Submission Meetings With OCP, CDER, and CDRH Use of Pre-Submission Meetings With OCP, CDER, and CDRH In the highly regulated fields of pharmaceutical products and medical devices, the proper understanding and preparation for regulatory submission are paramount. This article serves as a comprehensive guide on the use of pre-submission meetings with the Office of Combination Products (OCP), the Center for Drug Evaluation and Research (CDER), and the Center for Devices and Radiological Health (CDRH). It emphasizes actionable items and documentation requirements necessary to navigate the landscape of FDA combination product consulting efficiently. Step 1: Understanding the Regulatory Framework…

Design Control Requirements for Drug-Focused Combination Products Design Control Requirements for Drug-Focused Combination Products Design controls are a critical aspect of product development and regulation for combination products in the United States. Understanding the regulatory landscape surrounding FDA combination products is essential for successful drug development. This guide provides a comprehensive, step-by-step approach to navigating design control requirements for drug-focused combination products, including practical actions and documentation expectations. Step 1: Understanding the Definition and Types of Combination Products The first step in compliant development of drug-focused combination products is understanding what constitutes these products. According to the FDA, combination products…